Abstract: The invention pertains to host cells for producing a bioconjugate of an E. coli O18 antigen polysaccharide conjugated to a carrier protein. The host cells are characterized in that they comprise modified Wzy O-antigen polymerases with specific combinations of amino acid substitutions in one or more of positions 199, 377 and 395 as compared to the wild type Wzy O-antigen polymerase of SEQ ID NO: 1, which modified Wzy O-antigen polymerases improve the yield and glycosylation pattern of the O18 bioconjugates produced by the host cells. The invention further relates to methods wherein the host cells are used to produce a bioconjugate of an E. coli O18 antigen polysaccharide conjugated to a carrier protein, compositions comprising these bioconjugates, including multivalent compositions comprising bioconjugates of additional O antigen polysaccharide-serotypes.

Abstract: In general, systems and methods for controlling operation of drug administration devices using surgical hubs are provided.

Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigen O75 covalently bound to a carrier protein for the prevention of invasive ExPEC disease.

Abstract: An injection device and an injection device trainer for training a user to use an injection device. Each one of the injection device and the injection device trainer can include: a body portion; an actuator positioned towards a proximal end of the body portion, the actuator moveable from a proximal position to a distal position; a shield positioned towards a distal end of the body portion, the shield moveable between: an initial position; a retracted position that is more proximal relative to the body portion than the initial position; and an extended position that is more distal relative to the body portion than the initial position; and a locking member rotatable between a first orientation in which the locking member resists movement of the actuator from the proximal position to the distal position; and a second orientation in which the locking member permits the actuator to move from the proximal position to the distal position.

Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).

Abstract: The present disclosure relates to compositions, including oral compositions in the form of tablets, comprising aticaprant and methods of using the same.

Abstract: The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Abstract: The disclosure provides crystalline and amorphous forms of aticaprant. Also provided by the disclosure are pharmaceutical compositions comprising the amorphous or crystalline forms, methods of treating major depressive disorder using the amorphous or crystalline forms of aticaprant, amorphous or crystalline forms of aticaprant for use in the treatment of major depressive disorder in a human patient having anhedonia, uses of the amorphous or crystalline forms of aticaprant in the manufacture of a medicament for the treatment of major depressive disorder, and packages or pharmaceutical products comprising (i) amorphous or crystalline forms of aticaprant and (ii) instructions for treating major depressive disorder. In some aspects, the human patient treated as described herein has anhedonia.

Abstract: Various aspects of the subject technology relate to systems, methods, and machine-readable media for a learning platform that employs machine learning to identify patterns that describe meaningful subgroups of patients associated with a particular disease, distinct characteristics of each subgroup, and implications of belonging to a specific subgroup in terms of developing into a more severe disease state for patient journey mapping. The system may include a mapping server that includes a medical-event embedding engine that embeds electronic health records into vectors, a clustering engine that identifies clusters of patients with similar patient journeys by operating on the output of the medical-event embedding engine, and a cluster profiling engine that identifies distinguishing medical events for each identified cluster by operating on the output of the clustering engine.

Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

Abstract: In general, systems and methods for monitoring and communicating information using drug administration devices are provided.

Abstract: In general, systems and methods for monitoring and communicating information using drug administration devices are provided.

Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Abstract: An injection device and an injection device trainer for training a user to use an injection device. Each one of the injection device and the injection device trainer can include: a body portion; and an actuator positioned towards a proximal end of the body portion, the actuator moveable from a proximal position to a distal position; wherein the body portion comprises a body protrusion and the actuator comprises a latch that is arranged to couple with the body protrusion when the actuator is in the distal position, thus holding the actuator in the distal position.

Abstract: In general, drug administration devices that communicate with surgical hubs and methods of using drug administration devices that communicate with surgical hubs are provided. In one aspect, a surgical system is provided that in one embodiment includes a drug administration device configured to administer a drug to a patient during performance of a surgical procedure. The drug administration device includes a first communications interface and a first processor configured to cause the first communications interface to transmit data regarding operation of the drug administration device during the performance of the surgical procedure. The surgical system also includes a surgical hub including a second processor and a second communications interface. The second communications interface is configured to receive the transmitted data from the first communications interface during the performance of the surgical procedure.

Abstract: In general, systems and methods for patient monitoring using drug administration devices are provided.

Abstract: The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.